Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.02.2023 | Case report

Tozinameran

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lasagna A, et al. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern. ESMO Open 7: 100574, No. 5, Oct 2022. Available from: URL: https://www.journals.elsevier.com/esmo-open/ Lasagna A, et al. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern. ESMO Open 7: 100574, No. 5, Oct 2022. Available from: URL: https://​www.​journals.​elsevier.​com/​esmo-open/​
Metadaten
Titel
Tozinameran
Lack of efficacy: case report
Publikationsdatum
01.02.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-34056-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Hydromorphone

Case report

Budesonide

Case report

Alteplase

Case report

Azacitidine